Patent ID: 6218400
Filing Date: 2001-04-17
Classification: A61P,C07D

Abstract:
A method of treating conditions where inhibition of cGMP-specific PDE is of therapeutic benefit, in a human or nonhuman animal body, which comprises administering to said body a therapeutically effective amount of a compound having a formula ##STR11##and salts and solvates thereof, in which:R.sup.0 represents hydrogen, halogen, or C.sub.1-6 alkyl;R.sup.1 is selected from the group consisting of:(a) hydrogen;(b) C.sub.1-6 alkyl optionally substituted by one or more substituents selected from phenyl, halogen, --CO.sub.2 R.sup.a and --NR.sup.a R.sup.b ;(c) C.sub.3-6 -cycloalkyl;(d) phenyl; and(e) a 5- or 6-membered heterocyclic ring selected from the group consisting of pyridyl, morpholinyl, piperazinyl, pyrrolidinyl, and piperidinyl, and being optionally substituted by one or more C.sub.1-6 alkyl, and optionally linked to the nitrogen atom to which R.sup.1 is attached via C.sub.1-6 alkyl;R.sup.2 is selected from the group consisting of:(f) phenyl optionally substituted by one or more substituents selected from --OR.sup.a, --NR.sup.a R.sup.b, halogen, hydroxy, trifluoromethyl, cyano, and nitro;and R.sup.a and R.sup.b independently represent hydrogen or C.sub.1-6 alkyl.